Press Releases

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). AC0176 is an orally bioavailable, chimeric degrader molecule designed to target and degrade androgen receptor (AR) with high potency,

Healis Therapeutics, a privately held biotechnology company, today announces its mission to deliver a new class of neuromuscular therapeutics in psychiatry. Healis Co-Founder and CEO Dr. Eric Finzi made global headlines when he published the first trial showing efficacy of botulinum toxin in treating major depressive disorder (MDD) in 2006. Subsequently, five Phase II clinical trials have shown the effectiveness of botulinum toxin as a treatment for depression. Healis Ther

In the aftermath of the COVID-19 crisis, the pharmaceutical and biotech industries face a lot of uncertainties. The pharmaceutical industry has seen such an impact, that going back to pre-Covid19 strategies does not make sense anymore. Accelerated licensing for specific products, interrupted supply chains, changed marked demands and challenges of social distancing for resource planning are just a few of the hurdles the pandemic imposed on pharmaceutical and biotech companies. Rethinking their

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU. Avacta partnered with Medusa Healthcare (“Medusa”) to obtain regulatory approval for the AffiDX® antigen test for consumer self-testin

Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it. Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of proteins,

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study of Inhaled Voriconazole Powder (TFF VORI) in asthma patients. TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and preventi

Mezzion Pharma Co.Ltd. announces that new data from its Phase 3 efficacy and safety trial (FUEL Trial) and its open label extension trial  that concerns the treatment of a very large subgroup of patients with congenital single ventricle heart disease (SVHD) who have Fontan physiology was presented to the U.S. Food and Drug Administration (FDA) in a Type C meeting held on Thursday, December 16, 2021.  Mezzion Pharma is pleased to report that this newly presented data from t

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases. “Cladribine has a uniqu

Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA), ulcerative colitis, and Crohn's disease in Asia (South Korea, Taiwan, Hong Kong and Singapore). In December 2019, Eisai signed a partnership agreement with Gilead Sciences K.K., a Japanese subsidiary of Gilead, for the di

CANbridge Pharmaceuticals, Inc. a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that James Xue, Ph.D., Founder, Chairman and CEO, attended the launch ceremony of the Chinese Red Cross Foundation (CRCF) Rare Disease Mutual Assistance Fund, at the China Rare Diseases Conference 2021, in Beijing, on December 18th, as the representative of CANbridge, one of the founding